Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Catumaxomab - Neovii Biotech

Drug Profile

Catumaxomab - Neovii Biotech

Alternative Names: Anti-CD3 anti-EpCAM monoclonal antibody; Anti-EpCAM anti-CD3 monoclonal antibody; LP-000; Removab

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lindis Biotech; TRION Pharma
  • Developer Lindis Biotech; Linton Pharm; Neovii Biotech; Swedish Orphan Biovitrum; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Gastric cancer; Malignant ascites
  • Phase I/II Bladder cancer
  • No development reported Colorectal cancer
  • Discontinued Carcinoma; Ovarian cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for clinical-Phase-Unknown development in Bladder-cancer in China (Parenteral)
  • 28 Nov 2023 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer(Recurrent) in China (Parenteral)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Recurrent, Second-line therapy or greater) in Germany (Intravesicular)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top